Dr. Oh on the Use of Abiraterone and Docetaxel in mCRPC

William K. Oh, MD
Published: Friday, Dec 15, 2017



William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).

The use of abiraterone and docetaxel was established in mCRPC, and there are many conversations about combinations. There are currently no clear answers to these questions.
 


William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the use of abiraterone acetate (Zytiga) and docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).

The use of abiraterone and docetaxel was established in mCRPC, and there are many conversations about combinations. There are currently no clear answers to these questions.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x